Semaglutide, an FDA-approved once-weekly injection, has been proven to help people lose weight and maintain it
TB-500 in G-actin sequestration, endothelial and keratinocyte migration, and cardiac and corneal repair models, with randomised placebo-controlled human data existing only for thymosin beta 4 as a topical ophthalmic formulation
Initial treatments may require several injections per week, followed by maintenance doses every month
GLP-1 agonists, in contrast, generally do not lead to excessively low blood sugar levels
Athletes may notice less postworkout fatigue and a quicker return to baseline when programs, sleep, and nutrition are in place